Tweeter button Delicious button Digg button Stumbleupon button
Fatty Liver Disease | Research And Markets: Fatty Liver Disease Global Clinical Trials Review, H2 2013: Profiles Players Such As Biovil …

DUBLIN–(BUSINESS WIRE)–

Research and Markets ( ) has announced the addition of the “Fatty Liver Disease Global Clinical Trials Review, H2, 2013″ report to their offering.

The clinical trial report, Fatty Liver Disease Global Clinical Trials Review, H2, 2013″ provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fatty Liver Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fatty Liver Disease.


Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations

– Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

– Listings of


Click here to view rest of article from original site


Facebook Twitter Email

Important Disclaimer: Article Comments provided are for general information purposes only and are not intended to substitute for informed professional medical, psychological, tax, accounting, legal, investment, or any other professional advice. We expressly disclaim liability for any product, manufacturer, distributor, service or service provider mentioned or any opinion expressed in these comments or anywhere else within the site. Lastly, we do not endorse any article or comment. Use at your own risk.